Akero Therapeutics Inc.

NASDAQ: AKRO · Real-Time Price · USD
49.17
-0.92 (-1.84%)
At close: Aug 15, 2025, 3:04 PM

Akero Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-252.06M -151.76M -112.03M -100.78M
Depreciation & Amortization
18K 29K 43K 41K
Stock-Based Compensation
29.7M 21.5M 23.24M 10.05M
Other Working Capital
990K -6.03M -5.43M 6.45M
Other Non-Cash Items
-10.76M -8.46M 689K 203K
Deferred Income Tax
n/a n/a n/a 1.07M
Change in Working Capital
3M -6.67M -4.46M 9.73M
Operating Cash Flow
-230.11M -145.37M -92.52M -79.68M
Capital Expenditures
-999K n/a n/a n/a
Cash Acquisitions
n/a n/a n/a n/a
Purchase of Investments
-516.04M -433.12M -101.45M -43.56M
Sales Maturities Of Investments
407.33M 209.5M 37.62M 85.84M
Other Investing Acitivies
n/a n/a n/a n/a
Investing Cash Flow
-109.71M -223.62M -63.83M 42.28M
Debt Repayment
10M 15M 10M n/a
Common Stock Repurchased
464K n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
12.77M 2.89M 4.43M n/a
Financial Cash Flow
445.85M 353.32M 255.63M 602K
Net Cash Flow
106.03M -15.67M 99.29M -36.8M
Free Cash Flow
-230.11M -145.37M -92.52M -79.68M